text:
Label: METRONIDAZOLE tablet
NDC Code(s):
50111-334-01, view more50111-334-02
- Packager: Teva Pharmaceuticals USA, Inc.
- Category: HUMAN PRESCRIPTION DRUG LABEL
- DEA Schedule: None
- Marketing Status: Abbreviated New Drug Application
Drug Label Information
Updated January 28, 2022
If you are a consumer or patient please visit this version.
- Download DRUG LABEL INFO: PDF XML
- Official Label (Printer Friendly)
Rx only
To reduce the development of drug-resistant bacteria and maintain the effectiveness of metronidazole and other antibacterial drugs, metronidazole should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria.
Metronidazole has been shown to be carcinogenic in mice and rats (see PRECAUTIONS). Unnecessary use of the drug should be avoided. Its use should be reserved for the conditions described in the INDICATIONS AND USAGE section below.
Metronidazole tablets USP, 250 mg or 500 mg is an oral formulation of the synthetic nitroimidazole antimicrobial, 1H-Imidazole-1-ethanol, 2-methyl-5-nitro, which has the following structural formula:
Metronidazole tablets, USP contain 250 mg or 500 mg of metronidazole, USP. Inactive ingredients include silicified microcrystalline cellulose, crospovidone, colloidal silicon dioxide and hydrogenated vegetable oil.
Disposition of metronidazole in the body is similar for both oral and intravenous dosage forms. Following oral administration, metronidazole is well absorbed, with peak plasma concentrations occurring between one and two hours after administration.
Plasma concentrations of metronidazole are proportional to the administered dose. Oral administration of 250 mg, 500 mg, or 2,000 mg produced peak plasma concentrations of 6 mcg/mL, 12 mcg/mL, and 40 mcg/mL, respectively. Studies reveal no significant bioavailability differences between males and females; however, because of weight differences, the resulting plasma levels in males are generally lower.
Metronidazole is the major component appearing in the plasma, with lesser quantities of metabolites also being present. Less than 20% of the circulating metronidazole is bound to plasma proteins. Metronidazole appears in cerebrospinal fluid, saliva, and breast milk in concentrations similar to those found in plasma. Bactericidal concentrations of metronidazole have also been detected in pus from hepatic abscesses.
The major route of elimination of metronidazole and its metabolites is via the urine (60% to 80% of the dose), with fecal excretion accounting for 6% to 15% of the dose. The metabolites that appear in the urine result primarily from side-chain oxidation [1-(β-hydroxyethyl)-2-hydroxymethyl-5-nitroimidazole and 2-methyl-5-nitroimidazole-1-yl-acetic acid] and glucuronide conjugation, with unchanged metronidazole accounting for approximately 20% of the total. Both the parent compound and the hydroxyl metabolite possess in vitro antimicrobial activity.
Renal clearance of metronidazole is approximately 10 mL/min/1.73 m2. The average elimination half-life of metronidazole in healthy subjects is eight hours.
Renal Impairment
Decreased renal function does not alter the single-dose pharmacokinetics of metronidazole.
Subjects with end-stage renal disease (ESRD; CLCR = 8.1 ± 9.1 mL/min) and who received a single intravenous infusion of metronidazole 500 mg had no significant change in metronidazole pharmacokinetics but had 2-fold higher Cmax of hydroxy-metronidazole and 5-fold higher Cmax of metronidazole acetate, compared to healthy subjects with normal renal function (CLCR = 126 ± 16 mL/min). Thus, on account of the potential accumulation of metronidazole metabolites in ESRD patients, monitoring for metronidazole associated adverse events is recommended (see PRECAUTIONS).
Effect of Dialysis
Following a single intravenous infusion or oral dose of metronidazole 500 mg, the clearance of metronidazole was investigated in ESRD subjects undergoing hemodialysis or continuous ambulatory peritoneal dialysis (CAPD). A hemodialysis session lasting for 4 to 8 hours removed 40% to 65% of the administered metronidazole dose, depending on the type of dialyzer membrane used and the duration of the dialysis session. If the administration of metronidazole cannot be separated from the dialysis session, supplementation of metronidazole dose following hemodialysis should be considered (see DOSAGE AND ADMINISTRATION). A peritoneal dialysis session lasting for 7.5 hours removed approximately 10% of the administered metronidazole dose. No adjustment in metronidazole dose is needed in ESRD patients undergoing CAPD.
Hepatic Impairment
Following a single intravenous infusion of 500 mg metronidazole, the mean AUC24 of metronidazole was higher by 114% in patients with severe (Child-Pugh C) hepatic impairment, and by 54% and 53% in patients with mild (Child-Pugh A) and moderate (Child-Pugh B) hepatic impairment, respectively, compared to healthy control subjects. There were no significant changes in the AUC24 of hydroxyl-metronidazole in these hepatically impaired patients. A reduction in metronidazole dosage by 50% is recommended in patients with severe (Child-Pugh C) hepatic impairment (see DOSAGE AND ADMINISTRATION). No dosage adjustment is needed for patients with mild to moderate hepatic impairment. Patients with mild to moderate hepatic impairment should be monitored for metronidazole associated adverse events (see PRECAUTIONS and DOSAGE AND ADMINISTRATION).
Geriatric Patients
Following a single 500 mg oral or IV dose of metronidazole, subjects >70 years old with no apparent renal or hepatic dysfunction had a 40% to 80% higher mean AUC of hydroxy-metronidazole (active metabolite), with no apparent increase in the mean AUC of metronidazole (parent compound), compared to young healthy controls <40 years old. In geriatric patients, monitoring for metronidazole associated adverse events is recommended (see PRECAUTIONS).
Pediatric Patients
In one study, newborn infants appeared to demonstrate diminished capacity to eliminate metronidazole. The elimination half-life, measured during the first 3 days of life, was inversely related to gestational age. In infants whose gestational ages were between 28 and 40 weeks, the corresponding elimination half-lives ranged from 109 to 22.5 hours.
Mechanism of Action
Metronidazole, a nitroimidazole, exerts antibacterial effects in an anaerobic environment against most obligate anaerobes. Once metronidazole enters the organism by passive diffusion and activated in the cytoplasm of susceptible anaerobic bacteria, it is reduced; this process includes intracellular electron transport proteins such as ferredoxin, transfer of an electron to the nitro group of the metronidazole, and formation of a short-lived nitroso free radical. Because of this alteration of the metronidazole molecule, a concentration gradient is created and maintained which promotes the drug's intracellular transport. The reduced form of metronidazole and free radicals can interact with DNA leading to inhibition of DNA synthesis and DNA degradation leading to death of the bacteria. The precise mechanism of action of metronidazole is unclear.
A potential for development of resistance exists against metronidazole.
Resistance may be due to multiple mechanisms that include decreased uptake of the drug, altered reduction efficiency, overexpression of the efflux pumps, inactivation of the drug, and/or increased DNA damage repair.
Metronidazole does not possess any clinically relevant activity against facultative anaerobes or obligate aerobes.
Antimicrobial Activity
Metronidazole has been shown to be active against most isolates of the following bacteria both in vitro and in clinical infections as described in the INDICATIONS AND USAGE section.
Gram-positive anaerobes
Clostridium species
Eubacterium species
Peptococcus species
Peptostreptococcus species
Gram-negative anaerobes
Bacteroides fragilis group (B. fragilis, B. distasonis, B. ovatus, B. thetaiotaomicron, B.vulgatus)
Fusobacterium species
Protozoal parasites
Entamoeba histolytica
Trichomonas vaginalis
The following in vitro data are available, but their clinical significance is unknown:
Metronidazole exhibits in vitro minimal inhibitory concentrations (MIC's) of 8 mcg/mL or less against most (≥90%) isolates of the following bacteria; however, the safety and effectiveness of metronidazole in treating clinical infections due to these bacteria have not been established in adequate and well-controlled clinical trials.
Gram-negative anaerobes
Bacteroides fragilis group (B. caccae, B. uniformis)
Prevotella species (P. bivia, P. buccae, P. disiens)
Symptomatic Trichomoniasis
Metronidazole tablets are indicated for the treatment of T. vaginalis infection in females and males when the presence of the trichomonad has been confirmed by appropriate laboratory procedures (wet smears and/or cultures).
Asymptomatic Trichomoniasis
Metronidazole tablets are indicated in the treatment of asymptomatic T. vaginalis infection in females when the organism is associated with endocervicitis, cervicitis, or cervical erosion. Since there is evidence that presence of the trichomonad can interfere with accurate assessment of abnormal cytological smears, additional smears should be performed after eradication of the parasite.
Treatment of Asymptomatic Sexual Partners
T. vaginalis infection is a venereal disease. Therefore, asymptomatic sexual partners of treated patients should be treated simultaneously if the organism has been found to be present, in order to prevent reinfection of the partner. The decision as to whether to treat an asymptomatic male partner who has a negative culture or one for whom no culture has been attempted is an individual one. In making this decision, it should be noted that there is evidence that a woman may become reinfected if her sexual partner is not treated. Also, since there can be considerable difficulty in isolating the organism from the asymptomatic male carrier, negative smears and cultures cannot be relied upon in this regard. In any event, the sexual partner should be treated with metronidazole tablets in cases of reinfection.
Metronidazole tablets are indicated in the treatment of acute intestinal amebiasis (amebic dysentery) and amebic liver abscess.
In amebic liver abscess, metronidazole tablets therapy does not obviate the need for aspiration or drainage of pus.
Anaerobic Bacterial Infections
Metronidazole tablets are indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Indicated surgical procedures should be performed in conjunction with metronidazole tablets therapy. In a mixed aerobic and anaerobic infection, antimicrobials appropriate for the treatment of the aerobic infection should be used in addition to metronidazole tablets.
INTRA-ABDOMINAL INFECTIONS, including peritonitis, intra-abdominal abscess, and liver abscess, caused by Bacteroides species including the B. fragilis group (B. fragilis, B. distasonis, B. ovatus, B. thetaiotaomicron, B. vulgatus), Clostridium species, Eubacterium species, Peptococcus species, and Peptostreptococcus species.
SKIN AND SKIN STRUCTURE INFECTIONS caused by Bacteroides species including the B. fragilis group, Clostridium species, Peptococcus species, Peptostreptococcus species, and Fusobacterium species.
GYNECOLOGIC INFECTIONS, including endometritis, endomyometritis, tubo-ovarian abscess, and postsurgical vaginal cuff infection, caused by Bacteroides species including the B. fragilis group, Clostridium species, Peptococcus species, Peptostreptococcus species, and Fusobacterium species.
BACTERIAL SEPTICEMIA caused by Bacteroides species including the B. fragilis group and Clostridium species.
BONE AND JOINT INFECTIONS, (as adjunctive therapy), caused by Bacteroides species including the B. fragilis group.
CENTRAL NERVOUS SYSTEM (CNS) INFECTIONS, including meningitis and brain abscess, caused by Bacteroides species including the B. fragilis group.
LOWER RESPIRATORY TRACT INFECTIONS, including pneumonia, empyema, and lung abscess, caused by Bacteroides species including the B. fragilis group.
ENDOCARDITIS caused by Bacteroides species including the B. fragilis group.
To reduce the development of drug-resistant bacteria and maintain the effectiveness of metronidazole tablets and other antibacterial drugs, metronidazole tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
Metronidazole tablets are contraindicated in patients with a prior history of hypersensitivity to metronidazole or other nitroimidazole derivatives.
In patients with trichomoniasis, metronidazole tablets are contraindicated during the first trimester of pregnancy (see PRECAUTIONS).
Psychotic Reaction with Disulfiram
Use of oral metronidazole is associated with psychotic reactions in alcoholic patients who were using disulfiram concurrently. Do not administer metronidazole to patients who have taken disulfiram within the last two weeks (see PRECAUTIONS, Drug Interactions).
Interaction with Alcohol
Use of oral metronidazole is associated with a disulfiram-like reaction to alcohol, including abdominal cramps, nausea, vomiting, headaches, and flushing. Discontinue consumption of alcohol or products containing propylene glycol during and for at least three days after therapy with metronidazole (see PRECAUTIONS, Drug Interactions).
Cockayne Syndrome
Metronidazole tablets are contraindicated in patients with Cockayne syndrome. Severe irreversible hepatotoxicity/acute liver failure with fatal outcomes have been reported after initiation of metronidazole in patients with Cockayne syndrome (see ADVERSE REACTIONS).
Central and Peripheral Nervous System Effects
Encephalopathy and peripheral neuropathy: Cases of encephalopathy and peripheral neuropathy (including optic neuropathy) have been reported with metronidazole.
Encephalopathy has been reported in association with cerebellar toxicity characterized by ataxia, dizziness, and dysarthria. CNS lesions seen on MRI have been described in reports of encephalopathy. CNS symptoms are generally reversible within days to weeks upon discontinuation of metronidazole. CNS lesions seen on MRI have also been described as reversible.
Peripheral neuropathy, mainly of sensory type has been reported and is characterized by numbness or paresthesia of an extremity.
Convulsive seizures have been reported in patients treated with metronidazole.
Aseptic meningitis: Cases of aseptic meningitis have been reported with metronidazole. Symptoms can occur within hours of dose administration and generally resolve after metronidazole therapy is discontinued.
The appearance of abnormal neurologic signs and symptoms demands the prompt evaluation of the benefit/risk ratio of the continuation of therapy (see ADVERSE REACTIONS).
Hepatic Impairment
Patients with hepatic impairment metabolize metronidazole slowly, with resultant accumulation of metronidazole in the plasma. For patients with severe hepatic impairment (Child-Pugh C), a reduced dose of metronidazole is recommended. For patients with mild to moderate hepatic impairment, no dosage adjustment is needed but these patients should be monitored for metronidazole associated adverse events (see CLINICAL PHARMACOLOGY and DOSAGE AND ADMINISTRATION).
Renal Impairment
Patients with end-stage renal disease may excrete metronidazole and metabolites slowly in the urine, resulting in significant accumulation of metronidazole metabolites. Monitoring for metronidazole associated adverse events is recommended (see CLINICAL PHARMACOLOGY).
Fungal Superinfections
Known or previously unrecognized candidiasis may present more prominent symptoms during therapy with metronidazole and requires treatment with a candidacidal agent.
Use in Patients with Blood Dyscrasias
Metronidazole is a nitroimidazole and should be used with caution in patients with evidence of or history of blood dyscrasia. A mild leukopenia has been observed during its administration; however, no persistent hematologic abnormalities attributable to metronidazole have been observed in clinical studies. Total and differential leukocyte counts are recommended before and after therapy.
Drug-Resistant Bacteria and Parasites
Prescribing metronidazole in the absence of a proven or strongly suspected bacterial or parasitic infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria and parasites.
Information for Patients
Interaction with Alcohol
Discontinue consumption of alcoholic beverages or products containing propylene glycol while taking metronidazole and for at least three days afterward because abdominal cramps, nausea, vomiting, headaches, and flushing may occur (see CONTRAINDICATIONS and PRECAUTIONS, Drug Interactions).
Treatment of Bacterial and Parasitic Infections
Patients should be counseled that metronidazole should only be used to treat bacterial and parasitic infections. Metronidazole does not treat viral infections (e.g., the common cold). When metronidazole is prescribed to treat a bacterial infection, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by metronidazole in the future.
Drug Interactions
Psychotic reactions have been reported in alcoholic patients who are using metronidazole and disulfiram concurrently. Metronidazole should not be given to patients who have taken disulfiram within the last two weeks (see CONTRAINDICATIONS).
Alcoholic Beverages
Abdominal cramps, nausea, vomiting, headaches, and flushing may occur if alcoholic beverages or products containing propylene glycol are consumed during or following metronidazole therapy (see CONTRAINDICATIONS).
Warfarin and other Oral Anticoagulants
Metronidazole has been reported to potentiate the anticoagulant effect of warfarin and other oral coumarin anticoagulants, resulting in a prolongation of prothrombin time. When metronidazole is prescribed for patients on this type of anticoagulant therapy, prothrombin time and INR should be carefully monitored.
In patients stabilized on relatively high doses of lithium, short-term metronidazole therapy has been associated with elevation of serum lithium and, in a few cases, signs of lithium toxicity. Serum lithium and serum creatinine levels should be obtained several days after beginning metronidazole to detect any increase that may precede clinical symptoms of lithium intoxication.
Metronidazole has been reported to increase plasma concentrations of busulfan, which can result in an increased risk for serious busulfan toxicity. Metronidazole should not be administered concomitantly with busulfan unless the benefit outweighs the risk. If no therapeutic alternatives to metronidazole are available, and concomitant administration with busulfan is medically needed, frequent monitoring of busulfan plasma concentration should be performed and the busulfan dose should be adjusted accordingly.
Drugs that Inhibit CYP450 Enzymes
The simultaneous administration of drugs that decrease microsomal liver enzyme activity, such as cimetidine, may prolong the half-life and decrease plasma clearance of metronidazole.
Drugs that Induce CYP450 Enzymes
The simultaneous administration of drugs that induce microsomal liver enzymes, such as phenytoin or phenobarbital, may accelerate the elimination of metronidazole, resulting in reduced plasma levels; impaired clearance of phenytoin has also been reported.
Drugs that Prolong the QT interval
QT prolongation has been reported, particularly when metronidazole was administered with drugs with the potential for prolonging the QT interval.
Drug/Laboratory Test Interactions
Metronidazole may interfere with certain types of determinations of serum chemistry values, such as aspartate aminotransferase (AST, SGOT), alanine aminotransferase (ALT, SGPT), lactate dehydrogenase (LDH), triglycerides, and glucose hexokinase. Values of zero may be observed. All of the assays in which interference has been reported involve enzymatic coupling of the assay to oxidation-reduction of nicotinamide adenine dinucleotide (NAD+NADH). Interference is due to the similarity in absorbance peaks of NADH (340 nm) and metronidazole (322 nm) at pH 7.
Carcinogenesis, Mutagenesis, Impairment of Fertility
Tumors affecting the liver, lungs, mammary, and lymphatic tissues have been detected in several studies of metronidazole in rats and mice, but not hamsters.
Pulmonary tumors have been observed in all six reported studies in the mouse, including one study in which the animals were dosed on an intermittent schedule (administration during every fourth week only). Malignant liver tumors were increased in male mice treated at approximately 1,500 mg/m2 (similar to the maximum recommended daily dose, based on body surface area comparisons). Malignant lymphomas and pulmonary neoplasms were also increased with lifetime feeding of the drug to mice. Mammary and hepatic tumors were increased among female rats administered oral metronidazole compared to concurrent controls. Two lifetime tumorigenicity studies in hamsters have been performed and reported to be negative.
Metronidazole has shown mutagenic activity in in vitro assay systems including the Ames test. Studies in mammals in vivo have failed to demonstrate a potential for genetic damage.
Metronidazole failed to produce any adverse effects on fertility or testicular function in male rats at doses up at 400 mg/kg/day (similar to the maximum recommended clinical dose, based on body surface area comparisons) for 28 days. However, rats treated at the same dose for 6 weeks or longer were infertile and showed severe degeneration of the seminiferous epithelium in the testes as well as marked decreases in testicular spermatid counts and epididymal sperm counts. Fertility was restored in most rats after an eight week, drug-free recovery period.
Teratogenic Effects
There are no adequate and well controlled studies of metronidazole in pregnant women. There are published data from case-control studies, cohort studies, and 2 meta-analyses that include more than 5,000 pregnant women who used metronidazole during pregnancy. Many studies included first trimester exposures. One study showed an increased risk of cleft lip, with or without cleft palate, in infants exposed to metronidazole in-utero; however, these findings were not confirmed. In addition, more than ten randomized placebo-controlled clinical trials enrolled more than 5,000 pregnant women to assess the use of antibiotic treatment (including metronidazole) for bacterial vaginosis on the incidence of preterm delivery. Most studies did not show an increased risk for congenital anomalies or other adverse fetal outcomes following metronidazole exposure during pregnancy. Three studies conducted to assess the risk of infant cancer following metronidazole exposure during pregnancy did not show an increased risk; however, the ability of these studies to detect such a signal was limited.
Metronidazole crosses the placental barrier and its effects on the human fetal organogenesis are not known. Reproduction studies have been performed in rats, rabbits, and mice at doses similar to the maximum recommended human dose based on body surface area comparisons. There was no evidence of harm to the fetus due to metronidazole.
Nursing Mothers
Metronidazole is present in human milk at concentrations similar to maternal serum levels, and infant serum levels can be close to or comparable to infant therapeutic levels. Because of the potential for tumorigenicity shown for metronidazole in mouse and rat studies, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother. Alternatively, a nursing mother may choose to pump and discard human milk for the duration of metronidazole therapy, and for 24 hours after therapy ends and feed her infant stored human milk or formula.
Geriatric Use
In elderly geriatric patients, monitoring for metronidazole associated adverse events is recommended (see CLINICAL PHARMACOLOGY, PRECAUTIONS). Decreased liver function in geriatric patients can result in increased concentrations of metronidazole that may necessitate adjustment of metronidazole dosage (see DOSAGE AND ADMINISTRATION).
The following reactions have been reported during treatment with metronidazole:
Central Nervous System: The most serious adverse reactions reported in patients treated with metronidazole have been convulsive seizures, encephalopathy, aseptic meningitis, optic and peripheral neuropathy, the latter characterized mainly by numbness or paresthesia of an extremity. Since persistent peripheral neuropathy has been reported in some patients receiving prolonged administration of metronidazole, patients should be specifically warned about these reactions and should be told to stop the drug and report immediately to their physicians if any neurologic symptoms occur. In addition, patients have reported headache, syncope, dizziness, vertigo, incoordination, ataxia, confusion, dysarthria, irritability, depression, weakness, and insomnia (see WARNINGS).
Gastrointestinal: The most common adverse reactions reported have been referable to the gastrointestinal tract, particularly nausea, sometimes accompanied by headache, anorexia, and occasionally vomiting; diarrhea; epigastric distress; and abdominal cramping and constipation.
Mouth: A sharp, unpleasant metallic taste is not unusual. Furry tongue, glossitis, and stomatitis have occurred; these may be associated with a sudden overgrowth of Candida which may occur during therapy.
Dermatologic: Erythematous rash and pruritus.
Hematopoietic: Reversible neutropenia (leukopenia); rarely, reversible thrombocytopenia.
Cardiovascular: QT prolongation has been reported, particularly when metronidazole was administered with drugs with the potential for prolonging the QT interval. Flattening of the T-wave may be seen in electrocardiographic tracings.
Hypersensitivity: Urticaria, erythematous rash, Stevens-Johnson Syndrome, toxic epidermal necrolysis, flushing, nasal congestion, dryness of the mouth (or vagina or vulva), and fever.
Renal: Dysuria, cystitis, polyuria, incontinence, and a sense of pelvic pressure. Instances of darkened urine have been reported by approximately one patient in 100,000. Although the pigment which is probably responsible for this phenomenon has not been positively identified, it is almost certainly a metabolite of metronidazole and seems to have no clinical significance.
Hepatic: Cases of severe irreversible hepatotoxicity/acute liver failure, including cases with fatal outcomes with very rapid onset after initiation of systemic use of metronidazole, have been reported in patients with Cockayne syndrome (latency from drug start to signs of liver failure as short as 2 days) (see CONTRAINDICATIONS).
Other: Proliferation of Candida in the vagina, dyspareunia, decrease of libido, proctitis, and fleeting joint pains sometimes resembling "serum sickness." Rare cases of pancreatitis, which generally abated on withdrawal of the drug, have been reported.
Patients with Crohn's disease are known to have an increased incidence of gastrointestinal and certain extraintestinal cancers. There have been some reports in the medical literature of breast and colon cancer in Crohn's disease patients who have been treated with metronidazole at high doses for extended periods of time. A cause and effect relationship has not been established. Crohn's disease is not an approved indication for metronidazole tablets.
To report SUSPECTED ADVERSE REACTIONS, contact Teva at 1-888-838-2872 or FDA at 1-800-FDA-1088 or http://www.fda.gov/medwatch.
Single oral doses of metronidazole, up to 15 g, have been reported in suicide attempts and accidental overdoses. Symptoms reported include nausea, vomiting, and ataxia.
Oral metronidazole has been studied as a radiation sensitizer in the treatment of malignant tumors. Neurotoxic effects, including seizures and peripheral neuropathy, have been reported after 5 to 7 days of doses of 6 to 10.4 g every other day.
In the Female
One-day treatment - Two grams of metronidazole tablets, given either as a single dose or in two divided doses of one gram each, given in the same day.
Seven-day course of treatment - 250 mg three times daily for seven consecutive days. There is some indication from controlled comparative studies that cure rates as determined by vaginal smears and signs and symptoms, may be higher after a seven-day course of treatment than after a one-day treatment regimen.
The dosage regimen should be individualized. Single-dose treatment can assure compliance, especially if administered under supervision, in those patients who cannot be relied on to continue the seven-day regimen. A seven-day course of treatment may minimize reinfection by protecting the patient long enough for the sexual contacts to obtain appropriate treatment. Further, some patients may tolerate one treatment regimen better than the other.
Pregnant patients should not be treated during the first trimester (see CONTRAINDICATIONS). In pregnant patients for whom alternative treatment has been inadequate, the one-day course of therapy should not be used, as it results in higher serum levels which can reach the fetal circulation (see PRECAUTIONS, Pregnancy).
When repeat courses of the drug are required, it is recommended that an interval of four to six weeks elapse between courses and that the presence of the trichomonad be reconfirmed by appropriate laboratory measures. Total and differential leukocyte counts should be made before and after re-treatment.
In the Male: Treatment should be individualized as it is for the female.
For acute intestinal amebiasis (acute amebic dysentery): 750 mg orally three times daily for 5 to 10 days.
For amebic liver abscess: 500 mg or 750 mg orally three times daily for 5 to 10 days.
Pediatric patients: 35 to 50 mg/kg/24 hours, divided into three doses, orally for 10 days.
Anaerobic Bacterial Infections
In the treatment of most serious anaerobic infections, intravenous metronidazole is usually administered initially.
The usual adult oral dosage is 7.5 mg/kg every six hours (approx. 500 mg for a 70-kg adult). A maximum of 4 g should not be exceeded during a 24-hour period.
The usual duration of therapy is 7 to 10 days; however, infections of the bone and joint, lower respiratory tract, and endocardium may require longer treatment.
Dosage Adjustments
Patients with Severe Hepatic Impairment
For patients with severe hepatic impairment (Child-Pugh C), the dose of metronidazole tablets should be reduced by 50% (see CLINICAL PHARMACOLOGY and PRECAUTIONS).
Patients Undergoing Hemodialysis:
Hemodialysis removes significant amounts of metronidazole and its metabolites from systemic circulation. The clearance of metronidazole will depend on the type of dialysis membrane used, the duration of the dialysis session, and other factors. If the administration of metronidazole cannot be separated from the hemodialysis session, supplementation of metronidazole dosage following the hemodialysis session should be considered, depending on the patient's clinical situation (see CLINICAL PHARMACOLOGY).
Metronidazole Tablets, USP are available as follows:
250 mg - White, round, convex tablets debossed "PLIVA 333" on one side and unscored on the other side. Available in bottles of 100 (NDC 50111-333-01), 250 (NDC 50111-333-06) and 500 (NDC 50111-333-02).
500 mg - White, oblong, convex tablets debossed "PLIVA 334" on one side and unscored on the other side. Available in bottles of 100 (NDC 50111-334-01) and 500 (NDC 50111-334-02).
Storage and Stability
Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature].
Dispense in a tight, light-resistant container as defined in the USP, with a child-resistant closure (as required).
Manufactured In Czech Republic By:
Teva Czech Industries s.r.o.
Opava-Komarov, Czech Republic
Manufactured For:
Teva Pharmaceuticals USA, Inc.
North Wales, PA 19454
Rev. G 1/2022
- Package/Label Display Panel
- Package/Label Display Panel
metronidazole tablet
Product Information Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:50111-333 Route of Administration ORAL Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strength METRONIDAZOLE (UNII: 140QMO216E) (METRONIDAZOLE - UNII:140QMO216E) METRONIDAZOLE 250 mg Inactive Ingredients Ingredient Name Strength MICROCRYSTALLINE CELLULOSE (UNII: OP1R32D61U) CROSPOVIDONE (15 MPA.S AT 5%) (UNII: 68401960MK) SILICON DIOXIDE (UNII: ETJ7Z6XBU4) HYDROGENATED COTTONSEED OIL (UNII: Z82Y2C65EA) Product Characteristics Color white Score no score Shape ROUND Size 9mm Flavor Imprint Code PLIVA;333 Contains Packaging # Item Code Package Description Marketing Start Date Marketing End Date 1 NDC:50111-333-01 100 in 1 BOTTLE; Type 0: Not a Combination Product 09/30/1990 2 NDC:50111-333-06 250 in 1 BOTTLE; Type 0: Not a Combination Product 09/30/1990 3 NDC:50111-333-02 500 in 1 BOTTLE; Type 0: Not a Combination Product 09/30/1990 Marketing Information Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date ANDA ANDA070027 09/30/1990 METRONIDAZOLE
metronidazole tablet
Product Information Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:50111-334 Route of Administration ORAL Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strength METRONIDAZOLE (UNII: 140QMO216E) (METRONIDAZOLE - UNII:140QMO216E) METRONIDAZOLE 500 mg Inactive Ingredients Ingredient Name Strength MICROCRYSTALLINE CELLULOSE (UNII: OP1R32D61U) CROSPOVIDONE (15 MPA.S AT 5%) (UNII: 68401960MK) SILICON DIOXIDE (UNII: ETJ7Z6XBU4) HYDROGENATED COTTONSEED OIL (UNII: Z82Y2C65EA) Product Characteristics Color white Score no score Shape OVAL (oblong) Size 16mm Flavor Imprint Code PLIVA;334 Contains Packaging # Item Code Package Description Marketing Start Date Marketing End Date 1 NDC:50111-334-01 100 in 1 BOTTLE; Type 0: Not a Combination Product 09/30/1990 2 NDC:50111-334-02 500 in 1 BOTTLE; Type 0: Not a Combination Product 09/30/1990 Marketing Information Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date ANDA ANDA070033 09/30/1990 Labeler - Teva Pharmaceuticals USA, Inc. (001627975)


text:
Star & Leopard Print Sleeves Top
Star & Leopard Print Sleeves Top
Solid top with star and leopard print sleeves
Model Size Height: 5' 8" Bust: 32 Waist: 25 Hips: 35
Wearing size Small: 2 in US size
Made in USA
Shipping & Returns
Shipping & Returns
Online orders will be processed and shipped within 1-4 business days from date of purchase, with tracking. Orders placed on the weekend will be processed the next business day, as our warehouse is closed on weekends. Orders placed on a Holiday will be processed within 1-5 business days after the Holiday.
Hopefully you love everything you have purchased, but if something does not work out, you may return for a refund. We only offer STORE CREDIT for returns. We don't issue refunds back to your method of payment.
See our Boutique Policies page for more info.
Size Guide
Size Guide
The sizing of our clothes can sometimes vary depending on the cut/design of the garment and the fabric. However, we do try to remain consistent with our sizing, so that if you find you're normally a medium in our styles, then this should be true unless otherwise noted. We know how frustrating it can be to figure out the right size, so if you have questions about the fit of a specific garment, please do not hesitate to contact us. We would be more than happy to assist you with your fit question!
Otherwise, in general, a good guide for the way our clothing fits is as follows:
X-Small fits a size 0
Small fits sizes 2 and 4
Medium fits sizes 6 and 8
Large fits sizes 10 and 12
X-Large fits a size 14
About Our Collections
We carry a limited amount of stock for each style, which means the style turnover is quick. So be sure to grab the products you love when you see them: they might not be there the next time you stop by! New products and styles are released on a frequent basis. In addition to carrying our private label collection and name brands, we love being a boutique for local and regional artisans from our community to sell their lines.

subset: commoncrawl


text:
Dental Crowns in New Gloucester, ME
- Cover dental implants
- Prevent a cracked tooth from becoming worse
- Restore an existing filling in jeopardy of becoming loose or dislocated
Looking for an improved appearance for your smile? When applied to discolored or stained teeth needing restoration, dental crowns provide the appearance of natural teeth.
Dental Crown Aftercare
Once your dental crown is in place, it is important to maintain proper care of your teeth. While a crown has restored a tooth, it doesn't mean the tooth is indestructible. With proper care, a good quality crown can last up to eight or more years. Remember to brush and floss the area of the crown daily to avoid excess plaque buildup or collection of debris around the restoration.
It is also important to pay attention to other behaviors that might damage the dental crown. These behaviors often include jaw clenching or bruxism (teeth grinding). Try to avoid eating brittle foods, ice or hard candy as well. In doing so, the adhesion of the crown can be compromised or damaged.
Contact Pineland Family Dentistry today to learn about dental crowns in New Gloucester and how this restoration procedure might be able to restore the appearance and functionality of your smile.


text:
- California Gold Nutrition LactoBif Probiotics
- Available in 5, 30 & 100 Billion CFU per Veggie Capsule
- Exclusively using FloraFIT® Probiotics by Danisco®
- 8 Active & Clinically Researched Probiotic Strains¹
- Individually Double-foil Blister Sealed
- No Refrigeration Necessary²
- Suitable for Vegetarians & Vegans
- Formulated to Contain: No Dairy, No Gluten, No GMOs, No Soy
- Produced in a 3rd Party Audited cGMP Registered (Certified) Facility
- iTested Quality Confirmed & 100% Gold Guarantee
California Gold Nutrition Lactobif Probiotic formulas contain 8 active and clinically researched probiotic strains (5 Lactobacilli & 3 Bifidobacteria) exclusively using FloraFIT® Probiotics from Danisco®.
Research suggests the probiotic strains within Lactobif Probiotic formulas are extremely resistant to low pH and gastrointestinal conditions (e.g. acid, bile, pepsin and pancreatin), as well as adhere to the intestinal cell lines.
Benefits of Individuality, Double-foil Blister Sealed Probiotics:
- Optimal Barrier to Oxygen, Moisture & Light
- Ensures Product Integrity & Protection
- Tamper Resistant & Tamper Evident
- Shelf Stable & No Refrigeration Necessary²
- Guaranteed Potency²
Creating homemade fermented foods such as yogurt, kefir, kvass, etc is an art that requires specific probiotic culture starter products. Our LactoBif is not formulated to be used as a starter but LactoBif Probiotic capsules can be opened and the powder inside added to smoothies, shakes, etc.
|Supplement Facts
|Serving Size: 1 Veggie Capsule
|Servings Per Container: 60
|Amount Per Serving
|% Daily Value
|Probiotic Bacteria Blend
|30 Billion CFU
|Composed of the following strains:
|Lactobacillus acidophilus (La-14)
|Bifidobacterium lactis (BI-04)
|Lactobacillus rhamnosus (Lr-32)
|Lactobacillus plantarum (Lp-115)
|Bifidobacterium longum (BI-05)
|Bifidobacterium breve (Bb-03)
|Lactobacillus casei (Lc-11)
|Lactobacillus salivarius (Ls-33)
|† Daily Value not established.
Suggested Use
Take 1 veggie capsule daily or as directed by a qualified healthcare professional. May be taken with or without food.
Other Ingredients
Microcrystalline cellulose, vegetable capsule (modified cellulose), magnesium stearate (non-GMO vegetable source), silica.
Note: LactoBif products contain powder that is not 100% pure white and often has a yellow hue or yellow flecks because it contains many probiotic strains as well as other ingredients needed to encapsulate the powder blend.
Not manufactured with milk, eggs, fish, crustacean shellfish, tree nuts, peanuts, wheat, soy, corn, gluten, salt, sugar or yeast. Produced in a cGMP compliant facility that processes other products containing these allergens or ingredients.
Potency guaranteed until expiration date when stored in a cool, dry place at 77ºF (25ºC) or below.
Keep out of reach of children.
²Room Temperature, Shelf-Stable: Best kept at or below 77ºF (25ºC).
Refrigeration is not required, but highly recommended. Exposing probiotics to higher than recommended storage temperatures may cause product degradation and the reduction of live and active probiotic bacteria. Potency guaranteed until expiration date when stored in a cool, dry place, at 77ºF (25ºC) or below.


text:
A-D Cup Seamless Invisible Bra Lycra Gluing Comfy Chest Stickers Nu Bra Free Bye Bra
Item Specifics:
Package included:
Product Code: 5973618
Availability: In Stock
Availability: In Stock
Ex Tax: $23.99
Ex Tax: $23.99
Product Description
Brand: NO
Item Specifics:
Item Type: Bras
Gender: Women
Decoration: Lace Embroidery
Style: Sexy/Push up/Deep V
Material: Nylon
Lining Material: Lycra Gluing
Support Type: Wireless
Thickness: Mid Thick
Cup Shape: Half Cup(1/2 Cup)
Closure Type: Front Closure
Strap Type: Strapless
Colors: Black,Nude
Size: A,B,C,D
Package included:
About Size:
Size may be 2cm/1 inch inaccuracy due to hand measure.These measurements are meant as a
guide to help you select the correct size. Please take your own measurements and choose your size
accordingly.we cannot accept responsibility for incorrect purchases.
About Color:
The precise color of the clothing items may vary depending on the specific monitor,the settings
and the lighting conditions.The items colors depicted should only be used as an approximate guide
About Review:
1. We try to make sure you have a pleasant shopping experience with us, so that we could do more business with you. If there is any dissatisfaction, please email us before leaving any 1 or 2 ratings, negative feedback .We will try our best to resolve the issues. Please give us the opportunity to resolve any problem.
2. If you are satisfied with our service, please leave us a 5 star positive feedback. Your recognition will make us more confident to develop business and serve you better.


text:
There are two steps which require different appliances, but they're quick and simple. First, put some fresh ricotta in a food processor and process until smooth. Next, use a mixer to beat egg whites to a stiff, glossy state. That's it. The rest was just a matter of folding things together. In a large mixing bowl, the ricotta was mixed with egg yolks, flour, some sugar, orange zest, and salt. Then, the egg whites were folded into that mixture. It all went into a springform pan and was baked for about one hour. There was no water bath, so no need to wrap the springform pan in foil. It really was a very easy cheesecake to make.
It came out of the oven puffed like a souffle, but it didn't drop like one. It settled into a flat shape with just a little ridge around the outside. The instructions in the book mention turning the cake out of the pan and then inverting it back right side up, but I'm not sure why. I just removed the outer ring of the springform pan and let it sit on the base of the pan. Once it cooled to room temperature, I chilled it in the refrigerator in an airtight container. This was a sleek, grown up kind of cheesecake. It had no crust, no cream cheese, and it wasn't as sweet as other cheesecakes I've made. The texture was lightened by the egg whites but still had some sense of density from the ricotta. It was mildly flavored with an orange accent, and would be perfect with espresso. Since I didn't think to buy some espresso beans, I served it with a strawberry coulis. Dark chocolate sauce would be another option or maybe a melted marmalade. I think this particular cheesecake could be taken in all kinds of directions with sauces and toppings, and it was pretty delicious all by itself too.


text:
2685 Boones Creek Rd.Suite 104Johnson City, TN 37615
Click on a thumbnail to enlarge the image.
*Rates for December 2023. Information displayed is accurate as of the date of the latest update and is subject to change without notice. Loan pricing can only be locked through a home mortgage consultant. Other restrictions may apply. The Rate/APR and other terms may vary from those displayed based on the creditworthiness of the borrower, the type of dwelling, whether the borrower is self-employed, the location of the property and other factors. Please contact a lender in your area to determine what rates you qualify for.
**Rates calculated from national averages. To determine rates in your area please contact your local lender.
© 2023 Properties Online, Inc. (PropertiesOnline.com) Content including property details, articles or opinions posed on this website have not been independently verified and cannot be guaranteed. All information offered within this website should be independently verified. Website content is provided at the reader's own risk and the reader will not hold the parties involved in creating, producing or delivering this information liable for any loss, injury, claim, liability, or damage of any kind resulting in any way from any errors in or omissions from the information. Laws and taxes vary from state to state. You should consult with your individual CPA or tax attorney when purchasing or selling real estate. By providing links to other sites Properties Online, Inc. does not guarantee, approve or endorse the information or products available at these sites, nor does a link indicate any association with or endorsement by the linked site to the agent, brokerage, brand or Properties Online, Inc. Privacy Policy


text:
Gifts of Stock or Appreciated Securities
How It Works
- You transfer appreciated stocks, bonds, or mutual fund shares you have owned for more than one year to Baptist Homes Foundation.
- Baptist Homes Foundation sells the securities and uses the proceeds for our ministry.
- You receive an immediate income tax deduction for the fair market value of the securities on the date of transfer (even if you originally paid much less for them).
- You pay no capital gains tax on the transfer when the stock is sold.
- Giving appreciated stock can be more beneficial than giving cash. The "cost" of your gift is often less than the deduction you gain by making it.
- More detail on gifts of stock and appreciated assets.
- You can use our Stock Transfer Instructions.
- Frequently asked questions on gifts of stock.
- Contact us so we can assist you through every step.


text:
Top German Chocolate Maker Fights For Its 'Natural' Reputation
If you're selling food in Germany, "natural" is good. It's a place that distrusts technological manipulation of what we eat.
Witness, for example, a 500-year-old law that allows beer-makers to use only three ingredients: water, barley and hops. The law has since been loosened slightly, but many brewers continue to abide by it for marketing reasons.
This helps explain a fierce court battle now underway between Ritter Sport, one of Germany's leading chocolate makers, and an organization called Stiftung Warentest, which carries out tests of products (not just food) to see how they measure up to their marketing claims. Think of it as a German version of Consumers Union.
In late November, just before the big chocolate-buying season, Stiftung Warentest released a new report on Germany's chocolate options. In a stinging blow to Ritter Sport, the testers called Voll-Nuss, the company's top-selling nut-filled product, "deficient" — although they admitted that it did taste good.
The problem? It contained a chemical called piperonal, a vanilla-like aroma that Stiftung Warentest believes was manufactured using synthetic chemistry. In other words, unnatural.
Ritter Sport reacted like a goaded bull. The company declared that the piperonal in its chocolate has been extracted from natural sources, such as dill, violet flowers, black pepper, and vanilla. (According to European Union regulations, it is permissible to use either water or alcohol to extract "natural" flavors and aromas from herbs and other plants.) Ritter Sport then went to court, demanding that Stiftung Warentest retract its report.
The judge did, in fact, order Stiftung Warentest to stop making this claim until the case is resolved. It's still possible to order the report online, but all references to piperonal in the Ritter Sport chocolate have been blacked out, as if they were state secrets.
Stiftung Warentest admits that its tests cannot distinguish between synthetic piperonal and the same aroma extracted from herbs. It continues to insist, however, that Ritter Sport must be using the synthetic aroma because naturally obtained piperonal would be too expensive.
According to an account in Der Spiegel, a German newsmagazine, the judge in the case seems reluctant to rule in the case. At a recent hearing, he suggested that the two sides simply commission an independent audit to resolve the issue. The company and Stiftung Warentest refused. A decision isn't expected until early next year.
You care.
You want to know what is really going on these days, especially in Colorado. We can help you keep up. The Lookout is a free, daily email newsletter with news and happenings from all over Colorado. Sign up here and we will see you in the morning!


text:
Join singles across Swansea looking for friendship and love. Join for free and within seconds you can be searching for that special someone from our local database of singles. Our UK based customer support team is ready 24 hours a day to assist you and make your dating experience the best it can be.
We cover many areas of Swansea, including Manselton.
The first thing people see in your profile is your photograph. You want to make a good first impression right? Here are a few tips for you to pick that perfect picture.
You can add more than one photo to your profile, so if you want to add that "crayzee" night out with friends shot you can, just don't put it as your main picture.
So, what's an acronym? It's a short version of a phrase that usually contains the first letter of each word within the phrase. They have been around since, well, forever, but were particularly brought to the fore in the 1970s and 1980s with the advent of newspaper lonely hearts ads, as each word cost money and potential suitors wanted to keep their costs down! Nowadays, text speech contains many acronyms (as well as other bizarre shorthand words) so we're all pretty used to them, but do you know what they all mean?
WLTM Would like to meet
GSOH Good sense of humour
LTR Long-term relationship
F/ship Friendship
R/ship Relationship
ASL Age/sex/location
ASLP Age/sex/location/picture
F2F Face to face
IRL In real life
ND Non-drinker
NS Non-smoker
SD Social drinker
SS Social smoker
Div Divorced
DTE Down to earth
KWIM Know what I mean
LOL Laugh out loud/Lots of love
ROFL Rolling on the floor laughing
BRB Be right back
OMG Oh my God
LJBF Let's just be friends
POV Point of view
GTSY Glad to see you
GMTA Great minds think alike
AFK Away from keyboard
HAGN Have a good night
SYS See you soon
SWAK Sealed with a kiss
TX/THX Thanks
AML All my love


text:
This used pre-owned Harley-Davidson® Roadster is for sale at Route 66 Harley Davidson located in Tulsa, Oklahoma. Contact Route 66 Harley Davidson of Tulsa, Oklahoma today to schedule a test-ride. If this isn't the exact Harley-Davidson XL1200CX you're looking for don't hesitate to go back and revise your search. We're sure to have the perfect new or used motorcycle for you on our showroom in Tulsa, OK. Visit Route 66 Harley Davidson of Tulsa, your OK Harley-Davidson dealership. Oklahoma's premier new & used motorcycle dealer, we'll help you ride home on a new Harley-Davidson today!
Easy Financing. Call Today! 918-622-1340
Map Directions:3637 S Memorial Dr, Tulsa, OK 74145
Click to Call:918-622-1340


text:
UK Battery Test Equipment Industry Overview
At Plimsoll we do company and market analysis differently. Our unique, continuously updated analysis simplifies the complexity of financial data and a subscription gives you a clear insight into the health, value and prospects of the 25 leading UK Battery Test Equipment companies , and how they sit in the overall market.
Based on the data available today, here are some key findings this analysis flagged:
- Acquisitions: 1 company rated as "Highly Attractive"
- Benchmarking: 0 companies that are real up and coming threats
- Growth / New Business: 0 companies have grown by more than 10% in the latest year compared to 10.4% growth rates across the market
- Danger: 1 company is serial loss makers while companies are making the best profit
- Company Valuations: Get an instant valuation on 25 Battery Test Equipment companies showing who is up and who is falling
Companies included in this Industry Report
This industry belongs to the
Electrical & Electronics Sector
Industries in the Electrical & Electronics sector
Exceeded Validation Views
You have exceeded your allowance of free views.
If you would like to contact us to discuss this matter you can do so on +44 (0) 1642 626 470
Other Industries in the Electrical & Electronics sector
You have come from the Battery Test Equipment Industry which is part of the Electrical & Electronics Sector
= Closest related Industries to the Battery Test Equipment Industry
- Aerial & Satellite Installation
- Antennas
- Audio-Visual Equipment
- Barcode Equipment
- Battery Test Equipment
- Broadcast; Film & Video Equipment
- Cable & Wire Products Manufacturing
- Cable & Wire Suppliers
- Cable Installation
- Cable Management
- Camera Manufacturers & Suppliers
- Capacitor Manufacturers & Suppliers
- Car Audio & Entertainment Systems
- Communication Towers & Masts
- Contract Electronics Manufacturing
- Control Panel Manufacturers
- Digital Signage
- Domestic Appliances
- Earthing & Lightning Protection Products
- Educational Products & Supplies
- Electric Motors
- Electrical Contractors
- Electrical Retailers
- Electrical Testing & Inspection
- Electrical Wholesalers
- Electromagnetic Compatibility
- Electronic Cable Assemblies
- Electronic Component Distributors
- Electronic Connector Manufacturers & Suppliers
- Electronic Equipment Enclosures
- Electronic Equipment Manufacturers
- Emergency Lighting Manufacturers & Suppliers
- Energy Efficient Lighting
- Epos Systems & Software
- Fibre Optic Cabling Installation
- Fibre Optic Networking Products
- High Voltage Contractors
- Home Technology
- Lasers & Photonics
- Lighting
- Lighting Control Suppliers
- Lighting Design
- Lighting Installers
- Lighting Manufacturers
- Lighting Retailers
- Lighting Wholesalers & Distributors
- Lightning Protection Contractors
- Loudspeakers
- Microwave Components
- Mobile Phone Accessories
- Mobile Phone Distributors
- Mobile Phones
- Network & Data Communications
- Offshore Cable Solutions
- Photographic Supplies
- Printed Circuit Manufacturers
- Public Address Systems
- Radio Communications Equipment
- Rear View Camera Systems
- Satellite & Digital TV Equipment
- Satellite Communication Equipment
- Semiconductors
- Sensor Manufacturers
- Sound Equipment
- Stage Lighting & Equipment
- Street Lighting Contractors
- Switchgear Manufacturers & Suppliers
- Telecommunications Equipment & Systems
- Telecoms Distributors
- Telecoms Resellers
- Transformer Manufacturers
- Uninterruptible Power Supplies
Sector List
You have come from the Battery Test Equipment Industry which is part of the Electrical & Electronics Sector
Electrical & ElectronicsView Industries
Other Sectors
Agriculture & ForestryView Industries
AutomotiveView Industries
BeveragesView Industries
ChemicalView Industries
CleaningView Industries
ConstructionView Industries
Cosmetics & BeautyView Industries
Education & TrainingView Industries
EnergyView Industries
EnvironmentView Industries
Fashion & TextileView Industries
FinancialView Industries
FoodView Industries
Furniture & FurnishingsView Industries
Gardening & LandscapingView Industries
GlassView Industries
HealthcareView Industries
Heating, Ventilation & Air ConditioningView Industries
Hospitality & TravelView Industries
Industrial Goods & ServicesView Industries
Information TechnologyView Industries
LegalView Industries
Marketing, Advertising & PRView Industries
Media, Broadcasting & Performing ArtsView Industries
MetalsView Industries
MiscellaneousView Industries
Paper, Printing & PackagingView Industries
Pet CareView Industries
Professional ServicesView Industries
PropertyView Industries
PublishingView Industries
RetailView Industries
Scientific & TechnicalView Industries
SecurityView Industries
Sports & LeisureView Industries
TransportView Industries
UtilitiesView Industries
The Plimsoll Analysis is continuously updated to keep you up to date with the latest, most attractive acquisitions targets in the market. The following is a breakdown of the 1 best target currently identified by turnover:
Acquisition targets by size
Right now, directors of other companies are using a Plimsoll Analysis to find the best takeover targets in your market. In fact, the analysis has named 1 highly attractive targets that you need to look at first. The interactive nature of the analysis means you can instantly pick:
- 1 companies rated as "Highly Attractive"
- 22 rated as "Worth Considering"
- The best takeovers by region
- Targets by size
- Companies that you already have your eye on
- New takeover options as new data becomes available
- High growth / high takeover
Each company in the Plimsoll Analysis is rated on their attractiveness for takeover. A 9-point checklist is provided on each company to determine their attractiveness and this is presented in a simple "fuel gauge" style measure. The higher the gauge the more attractive the company.
The Plimsoll Analysis lets you benchmark your business performance against the competition and up to the minute industry metrics - all based on the continuously updated company data we receive. The following chart shows this weeks benchmarks in the Battery Test Equipment industry
Industry Growth
How do you compare to other Battery Test Equipment companies? Are you one of the best or do you aspire to join them? The Plimsoll Analysis gives you instant benchmark of your company alongside the other 24 leading Battery Test Equipment companies.
With an individual analysis and assessment on each company and a comprehensive industry overview complete with league performance tables, you will be able to instantly see:
- Where you sit in an industry averaging 10.4% growth and 2.3% profits
- The companies you are beating and the others outperforming you
- Performance targets you need to achieve to move up the rankings
- 0 companies that are real up and coming threats
Growth / New Business
The following chart shows the companies grabbing all the growth and those in decline, based on the latest data available.
Industry Sales Growth
With average growth in the UK Battery Test Equipment market reaching 10.4% in the latest year, the Plimsoll Analysis can help you benchmark your own growth, spot those achieving better and help formulate your next move.
Be the first to see who is achieving great success and which competitors are in decline including:
- 0 companies have grown by more than 10% in the latest year
- 10.4% growth rates across the market
- 10 companies are selling less than last year
- 11 companies have seen sales increase
The following chart shows the latest breakdown of ratings that the Plimsoll Analysis is currently showing:
As a further sign of the intense competition within the UK industry, 1 company continues to sell at a loss for the 2nd year running. These serial loss makers are adding to the congestion in the market, often undercutting the rest of the market and driving down profit margins across the board.
The Plimsoll Analysis provides an individual financial assessment on each company and will alert you instantly to how financially stable each company is. You will see:
- 11 companies that are making the best profit
- 0 that are high growth businesses changing the market
- 10 companies that are in decline
- 4 companies in danger
- 14 companies adding the most value
How about the ability to instantly compare your valuation to the latest valuations of 24 other Battery Test Equipment companies? The following charts show how company values have changed over the last 5 years.
Average change in value across the industry
Here are a few of the latest valuation based findings that have been flagged based on the most recent data:
- 3 companies have lost more than a quarter of their value in their latest year
- 14 companies are worth more than a year ago
- Average values are up more than 14% this year
Valuations are changing constantly as new financial data becomes available. You'll have access to an instant valuation on 25 Battery Test Equipment companies showing who is up and who is falling. The analysis also provides a valuation for each of the previous 4 years and also a "future year" showing what it could be worth.
The Plimsoll Analysis provides an individual financial and commercial appraisal of every company in any UK market. It provides intelligence and insight not available anywhere else and will change your opinion on companies you know and introduce you to interesting companies you were previously unaware of. The Plimsoll Analysis will show you:
- If a company is strong or heading for trouble
- If the value of the company is rising or falling
- How attractive the company would be for acquisition
- If they are turning their investments into higher growth and profits
- If new directors have enhanced the company's performance
- If the debts of the company are becoming a problem
- If they are continuing to chase sales despite falling profits
- If they are getting the most from their resources
The same model of analysis is provided on each company in a market. You will be able to compare the performance of any company in your market instantly and monitor key trends. You will also receive the following on each company:
- Breakdown of key board members
- Primary trading address
- All main shareholders
- List of subsidiaries
The Plimsoll Analysis also provides a top-level view of what is happening in the market. This section of the analysis will alert you to the changing nature of performance across the industry including:
- The overall size of the market
- The latest performance ranking tables (including growth, size, profitability and much more)
- The difference between small and large companies
- The latest industry benchmarks for profitability and growth
Want to know which companies have been included in the Plimsoll Analysis? Simply enter your details and we will send you a complete list of the companies individually analysed and valued in this Plimsoll Analysis:
We have an editing team with decades of experience who compile the companies that are included in the Plimsoll Analysis. We use a variety of sources to validate the accuracy of the list including Companies House, company websites, trade associations, search facilities and, of course, customer recommendations. If you want to add additional companies to your Plimsoll Analysis we can do that for you at no extra cost.
As we provide the analysis in our online format TALAT, our results are linked to those filed at Companies House. This data is fed into our analysis live so you have the latest analysis and valuations on each company in the market each time you consult the analysis.
In this Plimsoll Analysis, each company is individually analysed using the Plimsoll Model. This unrivalled model measures the performance of any company, large or small, showing trends over time, and has been the cornerstone of Plimsoll's unique analysis for more than three decades. Used by some of the world's largest companies, a Plimsoll Analysis gives instant comparative analysis of every company in any market. The model uses a series of intuitive charts and brief text-based summaries to highlight the key areas of interest in each company's performance. Each company is also valued and rated on their takeover attractiveness.
The data used for the Plimsoll Analysis is continuously updated via our live data feed. The Plimsoll Model of analysis on any company is guaranteed to be based on the latest financial data available today.
A comprehensive analysis of the latest trends in the market is also included so you see how the performance of a group of individual companies changes the direction of the market. In this section of the analysis, you will see performance ranking tables for growth, profitability and more, a breakdown of the latest industry averages and other key measures so you can put company performance into context.
The ranking tables and averages are changing continuously as we receive more up to date data. The Plimsoll Analysis is the only way for you to keep up with the latest developments across your market.
It couldn't be easier. The founder of Plimsoll developed the model so that all directors had a means of understanding a company's health and prospects – not just those with an accounting qualification. He knew that everyone could benefit from spotting companies that are heading for danger, those growing rapidly but suffering low margins, those most likely to fail and much more. Using a series of easy to understand, clearly labelled charts and simple written summaries he developed a model that empowered its reader and gave an instant opinion on every company from the large multinational to the tiniest operation. With the analysis being delivered in our online, interactive format, we can also ensure we keep you up to date with the latest changes in the market with continuously updated analysis.
We encourage all our clients to take advantage of our free demo service. One of our product specialists is on hand to provide a complete product demo to help you get the most from your Plimsoll Analysis. The online nature of our analysis also contains walkthrough guides to help you to get even more value and insight.
The Plimsoll Analysis is provided online in our exclusive format TALAT – Take A Look At That. Continuously updated to give you the most up to date view of individual companies and the wider market, our unique format of analysis includes a host of interactive features including:
- Ability to filter companies by size, region, growth, profitability, best acquisitions and much more
- Constantly updated company and industry analysis
- "Your Own" mini reports looking just at companies important to you
- Over 35 different categories of company performance at a click
- Synopsis and in-depth analysis and valuation on every company in the market
- Regional analysis showing companies in different parts of the UK
- Special Insight Reports – each month you will have access to in-depth studies on key developments in the market. Recent studies include "What is happening to values in the market?" and "Why Productivity is important to your competitiveness"
- Unlimited PDF report downloads
The analysis is linked to a live feed of constantly updated financial data. Every time you visit your Plimsoll Analysis you will have the most up to date valuation and performance analyses on any company and the latest snapshot on the key developments in the market.
For more than three decades our clients have used the Plimsoll Analysis to:
- Benchmark their own business performance
- Monitor their competition
- Reset their strategy goals in core markets
- Look for acquisition opportunities
- Assess business development and growth opportunities
- Vet trading partners
- Follow the trends in key markets
- Look in other markets for customers or suppliers
You can pay by credit card or if you prefer, we will invoice you and send a secure payment link to make payment. We accept all major credit cards and bank transfers.
The Plimsoll TALAT industry analysis is a subscription product but you are not committed to anything beyond the initial period of access that you purchased. We do not terminate your access at the end of that period without your permission because many of our customers personalise their analysis and we wouldn't want you to lose your favourites and personal reports. Your access to the Plimsoll analysis will automatically renew after your initial period but can be cancelled at that time if you no longer wish to continue with us- no questions asked.


text:
Global Visa Agent cares about your privacy. For this reason, we collect and use personal data only as it might be needed for us to deliver to you our world-class visa services and UK immigration services, (collectively, our "Services"). Your personal data includes information such as: • Name • Address • Telephone number • Date of birth • Email address • Other data collected that could directly or indirectly identify you for the purpose of processing your visa application or immigration application. Our Privacy Policy is intended to describe to you how and what data we collect, and how and why we use your personal data. It also describes options we provide for you to access, update or otherwise take control of your personal data that we process. If at any time you have questions about our practices or any of your rights described below, you may reach our Data Protection Officer ("DPO") and our dedicated team that supports this office by contacting us at INSERT EMAIL. This inbox is actively monitored and managed so that we can deliver an experience that you can confidently trust. Likewise, we've also created a Privacy Center to provide answers to your most common questions, quick links to access your Account Settings, instructions on how to exercise certain rights that might be available to you, and definitions to key terms and concepts noted in this Privacy Policy.
We collect information so that we can provide the best possible experience when you use our Services. Much of what you likely consider personal data is collected directly from you when you: (1) create an account or purchase any of our Services (ex: billing information, including name, address, credit card number, government identification); (2) request assistance from our customer support team (ex: phone number, email); (3) complete contact forms or request newsletters or other information from us (ex: email); or (4) participate in contests and surveys, apply for a job, or otherwise participate in activities we promote that might require information about you.
We collect additional information when delivering our Services to you to ensure necessary and optimal performance. These methods of collection may not be as obvious to you, so we wanted to highlight and explain below a bit more about what these might be (as they vary from time to time) and how they work:
Account related information is collected in association with your use of our Services, such as account number, purchases, when products renew or expire, information requests, and customer service requests and notes or details explaining what you asked for and how we responded.
Cookies and similar technologies on our websites and our mobile applications allow us to track your browsing behaviour, links clicked, items purchased, your device type, and to collect various data, including analytics, about how you use and interact with our Services. This allows us to provide you with more relevant product offerings, a better experience on our sites and mobile applications, and to collect, analyse and improve the performance of our Services. We may also collect your location (IP address) so that we can personalize our Services. For additional information, and to learn how to manage the technologies we utilize, please visit our Cookie Policy.
Data about Usage of Services is automatically collected when you use and interact with our Services, including metadata, log files, cookie/device IDs and location information. This information includes specific data about your interactions with the features, content and links (including those of third-parties, such as social media plugins) contained within the Services, Internet Protocol (IP) address, browser type and settings, the date and time the Services were used, information about browser configuration and plugins, language preferences and cookie data, information about devices accessing the Services, including type of device, what operating system is used, device settings, application IDs, unique device identifiers and error data, and some of this data collected might be capable of and be used to approximate your location.
Supplemented Data may be received about you from other sources, including publicly available databases or third parties from whom we have purchased data, in which case we may combine this data with information we already have about you so that we can update, expand and analyse the accuracy of our records, identify new customers, and provide products and services that may be of interest to you. If you provide us personal information about others, or if others give us your information, we will only use that information for the specific reason for which it was provided to us.
We strongly believe in both minimizing the data we collect and limiting its use and purpose to only that (1) for which we have been given permission, (2) as necessary to deliver the Services you purchase or interact with, or (3) as we might be required or permitted for legal compliance or other lawful purposes. These uses include:
1. Delivering, improving, updating and enhancing the Services we provide. We collect various information relating to your purchase, use and/or interactions with our Services. We use this information to:
• Improve and optimize the operation and performance of our Services (again, including our online application)
• Diagnose problems with and identify any security risks, errors, or needed enhancements to the Services
• Detect and prevent fraud and abuse of our Services and systems
• Collecting aggregate statistics about use of the Services
• Understand and analyse how you use our Services and what products and services are most relevant to you.
Often, much of the data collected is aggregated or statistical data about how individuals use our Services, and is not linked to any personal data, but to the extent it is itself personal data, or is linked or linkable to personal data, we treat it accordingly.
Sharing with trusted third parties. We may share your personal data with affiliated companies within our corporate family, with third parties with which we have partnered to allow you to integrate their services into our own Services, and with trusted third party service providers as necessary for them to perform services on our behalf, such as:
• Processing credit card payments
• Serving advertisements
• Conducting contests or surveys
• Performing analysis of our Services and customers demographics
• Communicating with you, such as by way email or survey delivery
• Customer relationship management.
We only share your personal data as necessary for any third party to provide the services as requested or as needed on our behalf. These third parties (and any subcontractors) are subject to strict data processing terms and conditions and are prohibited from utilizing, sharing or retaining your personal data for any other purpose than as they have been specifically contracted for (or without your consent).
2. Communicating with you. We may contact you directly or through a third party service provider regarding products or services you have signed up or purchased from us, such as necessary to deliver transactional or service related communications. We may also contact you with offers for additional services we think you'll find valuable if you give us consent, or where allowed based upon legitimate interests. You don't need to provide consent as a condition to purchase our goods or services. These contacts may include:
• Email
• Text (SMS) messages
• Telephone calls
• Automated phone calls or text messages and WhatsApp and other social media platforms.
You may also update your subscription preferences with respect to receiving communications from us and/or our partners by signing into your account and visiting "Account Settings" page.
If we collect information from you in connection with a co-branded offer, it will be clear at the point of collection who is collecting the information and whose privacy policy applies. In addition, it will describe any choice options you have in regards to the use and/or sharing of your personal data with a co-branded partner, as well as how to exercise those options.
If you make use of a service that allows you to import contacts (ex. using email marketing services to send emails on your behalf), we will only use the contacts and any other personal information for the requested service. If you believe that anyone has provided us with your personal information and you would like to request that it be removed from our database, please contact us at insert GDPR EMAIL.
Transfer of personal data abroad. If you utilize our Services from a country other than the country where our servers are located, your communications with us may result in transferring your personal data across international borders. Also, when you call us or initiate a chat, we may provide you with support from one of our global locations outside your country of origin. In these cases, your personal data is handled according to this Privacy Policy.
3. Compliance with legal, regulatory and law enforcement requests. We cooperate with government and law enforcement officials and private parties to enforce and comply with the law. We will disclose any information about you to government or law enforcement officials or private parties as we, in our sole discretion, believe necessary or appropriate to respond to claims and legal process (such as subpoena requests), to protect our property and rights or the property and rights of a third party, to protect the safety of the public or any person, or to prevent or stop activity we consider to be illegal or unethical.
To the extent we are legally permitted to do so, we will take reasonable steps to notify you in the event that we are required to provide your personal information to third parties as part of legal process.
4. To measure the effectiveness of digital marketing. We use multiple web analytics tools provided by service partners such as Google Analytics, and Singular to collect information about how you interact with our website or mobile applications, including what pages you visit, what site you visited prior to visiting our website, how much time you spend on each page, what operating system and web browser you use and network and IP information. We use the information provided by these tools to improve our Services. These tools place persistent cookies in your browser to identify you as a unique user the next time you visit our website. Each cookie cannot be used by anyone other than the service provider (ex: Google for Google Analytics). The information collected from the cookie may be transmitted to and stored by these service partners on servers in a country other than the country in which you reside. Though information collected does not include personal data such as name, address, billing information, etc., the information collected is used and shared by these service provider in accordance with their individual privacy policies. You can control the technologies we use by managing your settings through our Cookie Policy or the 'cookie banners" that may be presented (depending on URL of website visited) when you first visit our webpages, or by utilizing settings in your browser or third-party tools.
Third-party websites. Our website and our mobile applications contain links to third-party websites. We are not responsible for the privacy practices or the content of third-party sites. Please read the privacy policy of any website you visit.
To easily access, view, update, delete or port your personal data (where available), or to update your subscription preferences, please sign into your Account and visit "Account Settings." Please visit our Privacy Center for additional information and guidance for accessing, updating or deleting data.
If you make a request to delete your personal data and that data is necessary for the products or services you have purchased, the request will be honoured only to the extent it is no longer necessary for any Services purchased or required for our legitimate business purposes or legal or contractual record keeping requirements.
If you are unable for any reason to access your Account Settings or our Privacy Center, you may also contact us by one of the methods described in the "Contact Us" section below.
We follow generally accepted standards to store and protect the personal data we collect, both during transmission and once received and stored, including utilization of encryption where appropriate.
We retain personal data only for as long as necessary to provide the Services you have requested and thereafter for a variety of legitimate legal or business purposes. These might include retention periods:
• mandated by law, contract or similar obligations applicable to our business operations;
• for preserving, resolving, defending or enforcing our legal/contractual rights; or
• Needed to maintain adequate and accurate business and financial records.
If you have any questions about the security or retention of your personal data, you can contact us at INSERT GDPR EMAIL
Some browsers allow you to automatically notify websites you visit not to track you using a "Do Not Track" signal. There is no consensus among industry participants as to what "Do Not Track" means in this context. Like many websites and online services, we currently do not alter our practices when we receive a "Do Not Track" signal from a visitor's browser.
Our Services are available for purchase only for those over the age of 18. Our Services are not targeted to, intended to be consumed by or designed to entice individuals under the age of 18. If you know of or have reason to believe anyone under the age of 18 has provided us with any personal data, please contact us.
We reserve the right to modify this Privacy Policy at any time. If we decide to change our Privacy Policy, we will post those changes to this Privacy Policy and any other places we deem appropriate, so that you are aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If we make material changes to this Privacy Policy, we will notify you here, by email, or by means of a notice on our home page, at least thirty (30) days prior to the implementation of the changes.
If you are a resident of the European Economic Area (EEA) and believe we maintain your personal data subject to the General Data Protection Regulation (GDPR), you may direct questions or complaints to our lead supervisory authority, the German Federal Commisioner for Data Protection and Freedom of Information (Die Bundesbeauftrafte für den Datenschutz und die Informationsfreiheit), as noted below:
Husarenstraße 30
53117 Bonn, Germany
Phone: +49 228 997799 0; +49 228 81995 0
Fax: +49 228 997799 550; +49 228 81995 550
e-mail: firstname.lastname@example.com
If you have any questions, concerns or complaints about our privacy Policy, our practices or our Services, you may contact our Office of the DPO by email at INSERT EMAIL In the alternative, you may contact us by either of the following means:
By Mail: Global Visa Agent, Office 622, 5th Floor, Hyde Park Hayes 3, 11 Millington Road, Hayes, UB3 4AZ
By Phone: 020 77584545
We will respond to all requests, inquiries or concerns within thirty (30) days.


text:
The LXN-808 Radio Programming Software is designed to give you the ease and convenience of programming the memories and set menu options of your radio from your PC. Any memory channel with all its details can be sent to the radio with a simple keystroke.
Memory Channels Include:
Other Menu Item Categories Include:
The Radio Programmer Is for so Much More than Just Memory Management.
The programming process begins by first installing the program then installing (and allowing) the drivers for the cable. Be sure to complete both of these steps.
Save your file as you work. This is a computer, after all, and you would hate to lose your work should the system fail. Actually, create and save as many files as you want or need. You could have one file for home, a different one for the vacation house, another for the trip to your son's house, another for the yearly 3K run and picnic where you help direct traffic and want the radio to be programmed with only the frequencies for that event. Remember, radio programming is an overwrite process. Everything in the radio is replaced by everything in the file.
The program makes available the same VFOs as in the radio (usually one per band). Remember these are not real memory channels since the details are lost as soon as you tune the radio manually. There is no one button recall for these. You do not need to program into VFO before programming details into a memory channel. These channels are preprogrammed in the radio and while the frequency can be changed to another within the band, they cannot be left blank.
Radio Menu Settings
Common 1 and 2
Use these screens to customize many set menu features of the radio. Check boxes toggle features on or off, use drop down menus list all selections and blank boxes for personalized entry add to the ease of setting up your radio exactly like you want it.
The entries on the Settings screens are made for you to "Set and Forget". Once settings are customized, you are prompted to save before exiting. The saved settings will be there every time you create a new frequency file.
External Data
RT Systems Programmers interface with four sources of data to make it easy for you to find repeater information. Some of these sources even include information for repeaters outside the US. Your existing subscription to a service (where required) works in the programmer.
Radio Reference Search
An internet connection and subscription to the service are required for this search.
Repeater Book Search
An Internet connection is required for this search.
RFinder Search
An internet connection and subscription to the service are required for this search.
The information is returned on a screen that is not yet ready for radio programming, this screen lets you examine the data to see if the results are about what you expected. You might find that you spelled the city name wrong which resulted in nothing Being returned; or that you want to pull repeaters from further away; or you want to get repeaters for different bands.
Sorting Return Data
The screen that opens after you click OK for one of the external data searches gives you the ability to remove repeater information that your radio cannot use. You might have a radio that does not do DMR, DStar or Yaesu Fusion. Simply uncheck these in the list. The channels are removed from the list automatically.
Resulting File
After clicking Create File for (Your radio) the programmer creates the file that you use to program your radio. Notice that all the Tones are set up with the tone frequencies. All done automatically.
Grid Display
Memory Defaults
Click here to learn more about using Preferences to customize your radio programming experience.


text:
(This post began as a response to this comment by Julian Bond, in response to this post about Mad Men. When it got too long I decided to move it here.)
Smoking and drinking were standard back then. "Widespread" doesn't cover it. They were nearly universal.
It's easy to forget that Industry won WWII, and that the military-industrial complex crossed the whole society. All young men served in the military, either voluntarily or via the draft. Industry and its companion, Science, ruled. And — to an unhealthy degree — the former drove the latter.
Tobacco was an leading agricultural product, and cigarette manufacture was a leading industry that drove consumption through advertising so thick and ubiquitous — on TV and radio, in magazines, newspapers and on billboards — that for most people the only choice was which brand to smoke.
I remember thinking, as a child, that lighting sticks on fire and breathing the smoke was absurd and unhealthy on its face — and later being the only one of my high school friends who didn't smoke. But I was weird. Common sense then was pro-smoking.
Drinking and driving was only a little harder to rationalize. I remember statistics that said one in twenty-five drivers at night in the U.S. were drunk.
Industry and Science also together decided, among other things, that —
- Breast feeding was bad for babies, and "formula" was better. Thank you, Nestle.
- Children at birth should be taken from their mothers and stored in nurseries.
- All boys should all be circumcised at birth. So much for the Hippocratic oath: "First, do no harm."
- Tonsilitis" was a disease, and every severely sore throat should be treated surgically, involving removal of adenoids from the nose as well.
- Intestinal infections were likely to be appendicitis, so the appendix had to go too.
- Education is a manufacturing process, the purpose of which is to fill the empty vessels of childrens' heads with curricula approved by the State.
- Childrens' intelligence — their most unique and human quality — was a fixed quantity (a "quotient") that could be measured, as if by a dipstick, with IQ tests, so herds of students could be sorted into bell curves to better manage their progress through systems that regarded them — with the acquiescence of themselves and their parents — as "products" of their education.
I could go on. For what it's worth, I have my appendix, but lack tonsils, adenoids, spleen and foreskin, all of which were considered "vestigial" or otherwise bad by the medical fashions at the times of their removal. My known IQ scores have a range of 80 points. If my parents hadn't believed in me, my low IQ and standardized test scores in the 8th grade would have shunted me to a "vocational-technical" high school to learn wood shop, auto mechanics or some other "trade". I shall always be grateful for that.
Mad Men is close to home for me in another way: I was long in the advertising business too, though a generation after Mad Men's time, well after the "creative" revolution of the mid- to late 60s. It was one of the great periods in my life, but I've moved on. Similarly, I had a hard time watching the Sopranos, because I grew up in New Jersey, knew people like those, and was not entertained.
I think drugs and self-abuse are rituals of youth rationalized in their time by a sense of exemption from the due invoice we call aging. How long before fewer people are being tatooed than those having tattoos removed? I'm giving it 20 years.


text: Prenatal visits during the second trimester During the second and third trimester prenatal visits, your health care provider may check the following, depending on your current medical condition and your baby's health: any current symptoms or discomforts your weight your blood pressure urine test to detect albumin (a protein), which may indicate preeclampsia or toxemia, and sugar (glucose), which may indicate hyperglycemia growth, size and development of the fetus size of the uterus — after approximately 12 weeks of gestation, the uterus can be felt through the abdominal wall height of the fundus (top of the uterus), starting at 20 weeks of gestation fetal heartbeat What to expect during the second trimester The second trimester marks a turning point for mother and fetus. The mother usually begins to feel better and will start showing the pregnancy more. The fetus has now developed all its organs and systems and will now focus on growing in size and weight. During the second trimester, the umbilical cord continues to thicken as it carries nourishment to the fetus. However, harmful substances also pass through the umbilical cord to the fetus, so care should be taken to avoid alcohol, tobacco and other known hazards. During the second trimester, both the mother's body and the fetus continue to grow. Fetal development during the second trimester Now that all the major organs and systems have formed in the fetus, the following six months will be spent growing. The weight of the fetus will multiply more than seven times over the next few months, as the fetus becomes a baby that can survive outside of the uterus. By the end of the second trimester, the fetus will be about 13 to 16 inches long and weigh about 2 to 3 pounds. Fetal development during the second trimester includes the following: The fetus kicks and moves and can turn from side to side. The eyes have been gradually moving to the front of the face, and the ears have moved from the neck to the sides of the head. The fetus can hear the mother's voice. A creamy white substance (called vernix caseosa, or simply vernix) begins to appear on the fetus and helps to protect the thin fetal skin. Vernix is gradually absorbed by the skin, but some may be seen on babies even after birth. The fetus is developing reflexes, such as swallowing and sucking. The fetus can respond to certain stimuli. The placenta is fully developed. The brain will undergo its most important period of growth from the fifth month on. Fingernails have grown on the tips of the fingers and toes, and the fingers and toes are fully separated. The fetus goes through cycles of sleep and wakefulness. Skin is wrinkly and red, covered with soft, downy hair (called lanugo). Hair is growing on the head of the fetus. Fat begins to form on the fetus. Eyelids are beginning to open, and the eyebrows and eyelashes are visible. Fingerprints and toeprints have formed. The fetus is rapidly growing in size and weight. The 20th week marks the halfway point of the pregnancy. A fetus born at the end of 24 weeks may survive in a neonatal intensive care unit (NICU). Changes in the mother's body The second trimester is the most physically enjoyable for most women. Morning sickness usually abates by this time, and the extreme fatigue and breast tenderness usually subsides. These changes can be attributed to a decrease in levels of human chorionic gonadotropin (hCG) hormone and an adjustment to the levels of estrogen and progesterone hormones. The following is a list of changes and symptoms that may occur during the second trimester: Appetite may increase. The mother may be able to feel the movement of the fetus for the first time by 20 weeks. This is a phenomenon called quickening. The uterus has grown to the height of the belly button, making the pregnancy visible. The skin on the belly may itch as it grows, and there may be pain down the sides of the mother's body as the uterus stretches. The lower abdomen may ache as ligaments stretch to support the uterus. The need to frequently urinate may decrease as the uterus grows out of the pelvic cavity, relieving pressure on the bladder. A mother's nose may become congested, and she may experience nosebleeds. Her gums may become spongier and may bleed easily. Both of these things are due to the increase in hormones (estrogen and progesterone) that affect the mucous membranes in the nose and mouth. Varicose veins and hemorrhoids may appear. A woman may have a white-colored vaginal discharge called leukorrhea (a colored or bloody discharge may signal possible complications and should be examined immediately.) The increasing weight gain may cause backaches. Skin pigmentation may change on the face or abdomen due to the pregnancy hormones. Heartburn, indigestion and constipation may continue.


text:
Black Cherry Pearl - Urethane Basecoat with Premium Clearcoat Auto Paint - Complete Slow Gallon Paint Kit - Professional High Gloss Automotive Coating
Black Cherry Pearl - Urethane Basecoat with Premium Clearcoat Auto Paint - Complete Slow Gallon Paint Kit - Professional High Gloss Automotive Coating
Since 1974
- Complete 1 Gallon Restoration Shop Urethane Basecoat with Premium Clearcoat Auto Paint Kit with Slow Drying Reducer (Used during hot weather conditions when the temperatures are 85Á F and above). The kit provides 1-1/2 gallons (6 Quarts) of sprayable basecoat color material and 1-1/4 gallons (5 Quarts) of Premium Clearcoat.
- UB Paint Kit includes 1 Gallon of UB Urethane Basecoat Paint Color, 1 Gallon of UR85 Slow Urethane Reducer, 1 Gallon of HS3010 Premium High Solids Ultra Clear, 1 Quart of HS3030 Premium High Solids Hardener, 5 Pack of 190 Micron Nylon Automotive Strainers and a 5 Pack of Wood Paint Mixing Sticks.
- The Restoration Shop (UB) Urethane Basecoat and Premium Clearcoat System is a State-of-the-Art High-Performance Professional Easy-To-Use Paint Coating System that is Designed to Reproduce the Hi-Tech O.E.M. Automotive Finishes Found on Today's Vehicles.
- UB is an easy to spray fast-drying basecoat/clearcoat system that provides a long-lasting and very high gloss topcoat finish result. UB is an extremely durable, chemical and solvent resistant coating that also resists chipping, cracking, and UV ray fading.
- NOTE: Kit Not Available for Purchase in California or Other States with VOC limits below 3.5 VOC. Restoration Shop's (UBLV) is a Low 3.5 VOC compliant basecoat/clearcoat paint system that is available for purchase in 3.5 VOC limit States. Check your local air quality control district for more information on VOC rules and regulations in your area before purchasing.
- Note: Monitors vary - onscreen colors are for general color reference only.
- CALIFORNIA RESIDENTS: This item is not compliant for purchase in the State of California. If your shipping address is a California address you CANNOT purchase this item. Your order will be cancelled, NO EXCEPTIONS. California residents must purchase our UBLV LOW VOC Compliant Paint.


text:
Thank you for helping us improve the quality of Unity Documentation. Although we cannot accept all submissions, we do read each suggested change from our users and will make updates where applicable.Close
For some reason your suggested change could not be submitted. Please try again in a few minutes. And thank you for taking the time to help us improve the quality of Unity Documentation.Close
Build a Windows standalone.
See Also: BuildPipeline.BuildPlayer.